[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial von Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y, McJannett, Margaret M, Stockler, Martin R, Violet, John A, Williams, Scott G, Martin, Andrew J, Davis, Ian D, Azad, Arun A, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Ng, Siobhan, Pattison, David A, Ramdave, Shakher, Rana, Nisha, Redfern, Andrew D, Rutherford, Natalie K, Sandhu, Shahneen, Scott, Andrew M, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Violet, John A, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

Volltext

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in von Nowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia, Stockler, Martin R

Volltext

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a bio... von Buteau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Azad, Arun A, Banks, Patricia, Beaulieu, Alexis, Buteau, James P, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Kong, Grace, Kwan, Edmond M, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lewin, Jeremy, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Moodie, Kate, Murphy, Declan G, Ng, Siobhan, Pattison, David A, Pokorski, Izabella, Ramdave, Shakher, Ravi Kumar, Aravind S, Redfern, Andrew D, Rutherford, Natalie K, Saghebi, Javad, Sandhu, Shahneen, Scott, Andrew M, Spain, Lavinia, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Thang, Sue Ping, Tran, Ben, Wallace, Roslyn, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

Volltext

ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resis... von Emmett, Louise, Subramaniam, Shalini, Joshua, Anthony M., Crumbaker, Megan, Martin, Andrew, Zhang, Alison Y., Rana, Nisha, Langford, Ailsa, Mitchell, Jenna, Yip, Sonia, Francis, Roslyn, Hofman, Michael S., Sandhu, Shahneen, Azad, Arun, Gedye, Craig, McJannett, Margaret, Stockler, Martin R., Davis, Ian D.

Volltext

Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR) von Mercieca-Bebber, Rebecca, Williams, Douglas, Tait, Margaret-Ann, Roydhouse, Jessica, Busija, Lucy, Sundaram, Chindhu Shunmuga, Wilson, Michelle, Langford, Ailsa, Rutherford, Claudia, Roberts, Natasha, King, Madeleine, Vodicka, Elisabeth, Devine, Beth

Volltext

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial von Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, Davis, Ian D

Volltext

177LuLu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial von Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, Davis, Ian D

Volltext

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide... von Emmett, Louise, Subramaniam, Shalini, Zhang, Alison Yan, Martin, Andrew James, Yip, Sonia, Crumbaker, Megan, Rana, Nisha, Ford, Kate, Langford, Ailsa, Francis, Roslyn J., Hofman, Michael S, Joshua, Anthony M., Sandhu, Shahneen Kaur, Azad, Arun, Gedye, Craig, McJannett, Margaret Mary, Stockler, Martin R., Davis, Ian D.

Volltext

TheraP: A randomized phase II trial of [ 177 Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer von Hofman, Michael, Emmett, Louise, Violet, John A, Lawrence, Nicola Jane, Williams, Scott, Stockler, Martin R., Francis, Roslyn J, Iravani, Amir, Zhang, Alison Yan, Martin, Andrew James, Azad, Arun, Yip, Sonia, Langford, Ailsa, McJannett, Margaret Mary, Davis, Ian D.

Volltext

DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results von Nowak, Anna K., Lesterhuis, Willem Joost, Hughes, Brett Gordon Maxwell, Brown, Chris, Kok, Peey Sei, O'Byrne, Kenneth John, John, Tom, Pavlakis, Nick, Kao, Steven Chuan-Hao, Yip, Sonia, Karikios, Deme John, Lam, Wei-Sen, Langford, Ailsa, Stockler, Martin R.

Volltext

Correction to: Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR) von Mercieca-Bebber, Rebecca, Williams, Douglas, Tait, Margaret-Ann, Roydhouse, Jessica, Busija, Lucy, Sundaram, Chindhu Shunmuga, Wilson, Michelle, Langford, Ailsa, Rutherford, Claudia, Roberts, Natasha, King, Madeleine, Vodicka, Elisabeth, Devine, Beth

Volltext